Determination of the 161Tb half-life

There is significant interest in the use of terbium radioisotopes for applications in cancer therapy and diagnosis. Of these, Tb-161, as a medium energy beta-emitter, is being investigated as a potential alternative to Lu-177. The relatively high proportion of conversion electron and Auger electron emissions per decay make Tb-161 an attractive targeted therapeutic. As a product of nuclear fission, Tb-161 is also of importance to nuclear forensics. The standard uncertainty of the current evaluated half-life of 6.89(2) d contributes significantly to the standard uncertainty of any decay corrected activity determination made. Furthermore, the accuracy of this evaluated half-life has been called into question by measurements reported in 2020 at the Institute of Radiation Physics (IRA), Switzerland, who reported a half-life of 6.953(2) d. In the current work, the half-life of the Tb-161 ground state decay has been measured at three independent laboratories located in the United Kingdom and the United States of America for a total of six determinations using three independent measurement techniques; gamma-ray spectrometry, ionisation chamber measurement and liquid scintillation counting. The half-life determined for Tb-161 of 6.9637(29) d confirms the observed 1% relative increase observed by IRA, though the reported half-lives in this work and at IRA are significantly different (zeta-score = 3.1).

Automated summary

There is significant interest in the use of terbium radioisotopes, particularly Tb-161, for cancer therapy and diagnosis. It is considered as a potential alternative to Lu-177 due to its medium energy beta-emission and attractive therapeutic properties. The current work confirms a half-life of 6.9637(29) days for Tb-161, which shows a 1% relative increase compared to previous measurements.